IL144995A0 - Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders - Google Patents

Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Info

Publication number
IL144995A0
IL144995A0 IL14499500A IL14499500A IL144995A0 IL 144995 A0 IL144995 A0 IL 144995A0 IL 14499500 A IL14499500 A IL 14499500A IL 14499500 A IL14499500 A IL 14499500A IL 144995 A0 IL144995 A0 IL 144995A0
Authority
IL
Israel
Prior art keywords
recombinant
treatment
mediated disorders
antagonists useful
antagonists
Prior art date
Application number
IL14499500A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of IL144995A0 publication Critical patent/IL144995A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14499500A 1999-03-19 2000-03-17 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders IL144995A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19
PCT/US2000/007349 WO2000056771A1 (en) 1999-03-19 2000-03-17 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Publications (1)

Publication Number Publication Date
IL144995A0 true IL144995A0 (en) 2002-06-30

Family

ID=22419067

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14499500A IL144995A0 (en) 1999-03-19 2000-03-17 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Country Status (28)

Country Link
US (2) US6706487B1 (de)
EP (2) EP1163271B1 (de)
JP (1) JP2002542769A (de)
KR (1) KR100697120B1 (de)
CN (1) CN1246335C (de)
AR (1) AR022952A1 (de)
AT (1) ATE402191T1 (de)
AU (1) AU764622B2 (de)
BR (1) BR0008688A (de)
CA (1) CA2368965C (de)
CO (1) CO5470287A1 (de)
CY (1) CY1108387T1 (de)
CZ (1) CZ303704B6 (de)
DE (1) DE60039589D1 (de)
DK (1) DK1163271T3 (de)
ES (1) ES2308974T3 (de)
HK (1) HK1043798B (de)
HU (1) HU228931B1 (de)
IL (1) IL144995A0 (de)
MY (1) MY124219A (de)
NO (1) NO330391B1 (de)
NZ (1) NZ513699A (de)
PL (1) PL202396B1 (de)
PT (1) PT1163271E (de)
SI (1) SI1163271T1 (de)
TR (3) TR200202253T2 (de)
WO (1) WO2000056771A1 (de)
ZA (1) ZA200107639B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
EP2338515A3 (de) * 2000-02-10 2011-11-16 Abbott Laboratories Humanes Interleukin-18 bindende Antikörper und Verfahren zu ihrer Herstellung und Verwendung
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1494710A4 (de) * 2002-03-26 2007-03-21 Centocor Inc Diabetes-relevante von immunoglobulin stammende proteine, zusammensetzungen, verfahren und verwendungszwecke
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004040969A1 (ja) * 2002-11-07 2004-05-21 Kumamoto Technology & Industry Foundation Ｇａｎｐ導入トランスジェニック哺乳動物及びその利用
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
EP2027157B1 (de) * 2006-05-25 2014-08-06 Glaxo Group Limited Modifizierte humanisierte anti-interleukin-18 antikörper
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2238166T1 (sl) 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
WO2009051220A1 (ja) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
HUE031944T2 (en) 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
EP2281004A4 (de) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc Prostataspezifische membranantigenantikörper und antigenbindende fragmente
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US20110150871A1 (en) * 2008-08-18 2011-06-23 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
US20110136601A1 (en) * 2009-06-30 2011-06-09 Gosen Co., Ltd. Racket string and method for producing the same and racket strung with the same
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2462162B1 (de) 2009-08-06 2016-10-12 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
EP2470568A2 (de) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutische dll4-bindende proteine
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EA201290630A1 (ru) * 2010-02-09 2013-03-29 Глаксо Груп Лимитед Лечение расстройства обмена веществ
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
SG10201501562VA (en) * 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
WO2011150086A2 (en) * 2010-05-25 2011-12-01 The Regents Of The University Of Colorado, A Body Corporate Diagnosis and treatment of autoimmune disease
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
RU2013133846A (ru) 2010-12-20 2015-01-27 Медиммьюн Лимитед Антитела против il-18 и их применение
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10570199B2 (en) 2012-11-21 2020-02-25 Km Biologics Co., Ltd. Human antibody against IL-18
MY194040A (en) * 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
JP2023530489A (ja) * 2020-06-18 2023-07-18 ネクストキュア インコーポレイテッド Ｆｌｒｔ３媒介性シグナル伝達を調節するための組成物及び方法
JPWO2023286694A1 (de) 2021-07-13 2023-01-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
EP1961768A1 (de) 2008-08-27
TR200202254T2 (tr) 2002-12-23
PT1163271E (pt) 2008-09-16
CY1108387T1 (el) 2014-02-12
PL350460A1 (en) 2002-12-16
ZA200107639B (en) 2002-09-17
EP1163271A1 (de) 2001-12-19
EP1163271A4 (de) 2003-04-09
EP1163271B1 (de) 2008-07-23
KR100697120B1 (ko) 2007-03-20
SI1163271T1 (sl) 2008-10-31
HK1043798B (zh) 2009-04-09
HK1043798A1 (en) 2002-09-27
KR20020008130A (ko) 2002-01-29
DK1163271T3 (da) 2008-11-10
HU228931B1 (en) 2013-06-28
HUP0200502A3 (en) 2003-12-29
CA2368965C (en) 2010-05-18
AU764622B2 (en) 2003-08-28
NO330391B1 (no) 2011-04-04
JP2002542769A (ja) 2002-12-17
NO20014524L (no) 2001-11-14
CZ303704B6 (cs) 2013-03-27
MY124219A (en) 2006-06-30
PL202396B1 (pl) 2009-06-30
ATE402191T1 (de) 2008-08-15
US6706487B1 (en) 2004-03-16
HUP0200502A2 (en) 2002-06-29
US20040141964A1 (en) 2004-07-22
NZ513699A (en) 2004-02-27
CO5470287A1 (es) 2004-12-30
ES2308974T3 (es) 2008-12-16
AR022952A1 (es) 2002-09-04
CN1352650A (zh) 2002-06-05
BR0008688A (pt) 2002-01-08
DE60039589D1 (de) 2008-09-04
CZ20013362A3 (cs) 2002-03-13
TR200202253T2 (tr) 2002-12-23
NO20014524D0 (no) 2001-09-18
AU3901600A (en) 2000-10-09
TR200102733T2 (tr) 2002-04-22
WO2000056771A1 (en) 2000-09-28
CN1246335C (zh) 2006-03-22
CA2368965A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
HUP0200502A2 (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
HUS1500070I1 (hu) IL-5-Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták
HK1109867A1 (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
HK1068885A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n--
IL153565A0 (en) 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
IL144954A0 (en) Quinazolines and therapeutic use thereof
IL157365A0 (en) Mch antagonists and their use in the treatment of obesity
GB0007193D0 (en) Treatment of movrmrnt disorders
EP1404343A4 (de) Therapeutische kombinationen zur behandlung von hormonmangelzuständen
IL149496A0 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
IL156781A0 (en) (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes
EP1416957A4 (de) Behandlung von immunerkrankungen und b-zellen-erkrankungen
PL369822A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
AU2003250831A8 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
PL351554A1 (en) Osanetant in the treatment of mood disorders
HUP0202339A3 (en) Use of cortisol antagonists in the treatment of heat failure
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
IL160551A0 (en) Plaster for the treatment of dysfunctions and disorders of nails
AU2002229091A1 (en) Secreted polypeptide and their use in the treatment of bone disorders

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired